FY25 guidance 25 November 2025 | 2:22AM HKT Equity Research JD Health International (6618.HK): Internet Trip takeaways: continued share gain across categories, drugs momentum to continue; Buy We hosted JD Health (JDH) Investor Relations team with investors on Nov 24 in Beijing during our China internet trip, where investors' key focus and our takeaways were centered around: 1) FY25 revenue and profit guidance; 2) recent trend by product category; 3) thoughts and investments on O2O initiatives; 4) update on ...

This story was originally published on Supply Chain Dive. To receive daily news and insights, subscribe to our free daily Supply Chain Dive newsletter. The United States secured new framework trade agreements last week that would lower one of its highest country-specific tariff rates while allowing certain duty exemptions for four nations in Central and South America. In a framework agreement with Switzerland and Liechtenstein, the U.S. said it would slash the current 39% tariff charged to imports of Swi ...

With a market cap of $54.2 billion, Becton, Dickinson and Company (BDX) is a leading medical technology firm headquartered in Franklin Lakes, New Jersey. The company develops, manufactures, and sells a wide range of medical devices, laboratory equipment, and diagnostic products used in healthcare, research, and clinical settings. BD operates through three key segments: BD Medical, BD Life Sciences, and BD Interventional, serving hospitals, laboratories, and pharmaceutical companies worldwide. Shares of th ...

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying stocks that can fulfill their growth potential is challenging due to associated risks and volatility [1] Group 1: Company Overview - LeMaitre Vascular (LMAT) is identified as a promising growth stock with a favorable Growth Score and a top Zacks Rank [2] - The company has a historical EPS growth rate of 14.3%, with projected EPS growth of 28.4% this year, significantly surpassing the industry average of 13% [5] Group 2: Financial Metrics - LeMaitre's year-over-year cash flow growth stands at 35.1%, well above the industry average of 1.8%, indicating strong financial health [6] - The company's annualized cash flow growth rate over the past 3-5 years is 18.1%, compared to the industry average of 8.2% [7] Group 3: Earnings Estimates - There is a positive trend in earnings estimate revisions for LeMaitre, with the current-year earnings estimates increasing by 4.1% over the past month [8] - The combination of a Growth Score of B and a Zacks Rank 2 positions LeMaitre favorably for potential outperformance in the market [10]

Core Insights - Organon reported Q3 CY2025 results that exceeded market revenue expectations, with sales increasing by 1.3% year-on-year to $1.60 billion, beating analyst estimates by 2% [1][7][8] - The company's full-year revenue guidance of $6.23 billion at the midpoint is 1% below analysts' estimates [1][8] - Non-GAAP profit of $1.01 per share was 8.5% above analysts' consensus estimates [1][7] Company Overview - Organon was spun off from Merck in 2021, focusing on addressing unmet needs in women's health through various healthcare solutions [4] Revenue Growth - Over the last five years, Organon's revenue declined by 1.7% per year, indicating weak demand and a lack of business quality [5] - The company has shown an annualized revenue growth of 1.2% over the last two years, which is an improvement over the five-year trend, but still disappointing [6] Financial Performance - Adjusted EBITDA was reported at $518 million, with a margin of 32.3%, exceeding analyst estimates by 7.9% [7] - Operating margin decreased to 15.2%, down from 21.4% in the same quarter last year [7] - Market capitalization stands at $1.76 billion [7] Future Outlook - Analysts expect revenue to remain flat over the next 12 months, indicating potential demand headwinds for Organon's products and services [8]

Core Insights - SG Capital Management LLC reduced its holding in Haemonetics Corporation by 731,892 shares, resulting in a position value decline of approximately $59.1 million as of November 7, 2025 [1][2]. Company Overview - Haemonetics Corporation is a leading provider of medical devices and software for blood and plasma management, addressing critical needs in transfusion medicine and plasma collection through a diversified product portfolio and integrated technology platforms [5][6]. - The company generates revenue primarily from the sale of medical devices, disposables, and integrated software solutions to healthcare providers and plasma collection centers globally [6]. Financial Performance - For the trailing twelve months (TTM), Haemonetics reported revenue of $1.33 billion and net income of $168.19 million [4]. - The company's share price as of November 6, 2025, was $67.11, reflecting a 14.14% decline over the past year, underperforming the S&P 500 by 27.5 percentage points [4][10]. Recent Developments - Haemonetics reported a 5% decline in revenue for the fiscal second quarter, totaling $327 million, with a 1.8% drop when excluding foreign-currency exchange impacts and divestitures [8]. - Management's guidance for the full year's adjusted revenue indicates a potential decline of 1% to an increase of 2%, which is an improvement from previous guidance [9]. Investment Activity - Following the reduction in its stake, Haemonetics now accounts for only 0.8% of SG Capital's total 13F assets under management (AUM), down from 4.7% in the prior quarter [10]. - The market reacted positively to Haemonetics' results and guidance, with the share price increasing by 35% in the two days following the earnings release [11].

Businesses using passenger aircraft for domestic freight transportation could experience some shipping delays from the Federal Aviation Administration’s order for airlines to reduce their schedules at the nation’s busiest airports starting Friday because of the government shutdown, but the impact on all-cargo carriers is expected to be minimal, according to air logistics professionals. Freighter operators won’t be heavily exposed to flight reductions because the mandate applies to flights from 6 a.m. to 1 ...

Core Insights - McKesson reported quarterly earnings of $9.86 per share, exceeding the Zacks Consensus Estimate of $8.92 per share, and up from $7.07 per share a year ago, representing an earnings surprise of +10.54% [1][2] - The company posted revenues of $103.15 billion for the quarter ended September 2025, which missed the Zacks Consensus Estimate by 1.45%, compared to $93.65 billion in the same quarter last year [2] - McKesson's stock has increased approximately 47.7% year-to-date, significantly outperforming the S&P 500's gain of 15.1% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $9.99, with expected revenues of $105.75 billion, and for the current fiscal year, the EPS estimate is $38.05 on revenues of $409.17 billion [7] - The estimate revisions trend for McKesson was favorable prior to the earnings release, resulting in a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Dental Supplies industry, to which McKesson belongs, is currently ranked in the top 24% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - The performance of McKesson's stock may also be influenced by the overall industry outlook, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Hologic, with a focus on how actual results compare to estimates, which could significantly impact stock price [1][2]. Earnings Expectations - Hologic is expected to report earnings of $1.10 per share, reflecting an 8.9% increase year-over-year [3][18]. - Revenue is projected to be $1.03 billion, representing a 4.7% increase from the previous year [3][19]. Estimate Revisions - The consensus EPS estimate has been revised down by 1.38% over the last 30 days, indicating a reassessment by analysts [4][19]. - The Most Accurate Estimate matches the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, complicating predictions of an earnings beat [12][19]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with a strong predictor of earnings beats when combined with a favorable Zacks Rank [9][10]. - Hologic currently holds a Zacks Rank of 3 (Hold), making it challenging to predict an earnings beat conclusively [12][20]. Historical Performance - In the last reported quarter, Hologic exceeded the expected earnings of $1.05 per share, achieving $1.08, resulting in a surprise of +2.86% [13]. - Over the past four quarters, Hologic has surpassed consensus EPS estimates three times [14][20]. Conclusion - While Hologic is not positioned as a compelling earnings-beat candidate, investors should consider other factors when making decisions regarding the stock ahead of the earnings release [17][20].

Core Insights - Gentex Corporation reported consolidated net sales of $655.2 million for Q3 2025, an 8% increase from $608.5 million in Q3 2024, with VOXX contributing $84.9 million to the revenue [3][7] - Core Gentex revenue, excluding VOXX, was $570.3 million, reflecting a 6% decline compared to Q3 2024, despite a 2% increase in light vehicle production in primary markets [3][8] - The consolidated gross margin improved to 34.4%, up from 33.5% in Q3 2024, while the core Gentex gross margin was 34.9%, a 140 basis-point increase [4][7] Financial Performance - Consolidated income from operations was $122.3 million, down from $125.7 million in Q3 2024, with core Gentex income from operations at $119.7 million, a 5% decrease [8][11] - Consolidated net income attributable to Gentex was $101.0 million, compared to $122.5 million in Q3 2024, primarily due to a one-time gain in the prior period [11][12] - Earnings per diluted share were $0.46, down from $0.53 in Q3 2024, influenced by the previous one-time gain [12][11] Revenue Breakdown - Gentex Automotive net sales were $558.0 million in Q3 2025, down from $596.5 million in Q3 2024, attributed to lower shipments in Europe and China [13] - Other product lines generated $12.3 million in net sales, slightly up from $12.0 million in Q3 2024 [14] - VOXX's net sales contribution was $84.9 million, with ongoing efforts to align product strategies and optimize customer relationships post-acquisition [15] Operating Expenses - Consolidated operating expenses increased to $102.8 million from $78.3 million in Q3 2024, largely due to the VOXX acquisition [5][6] - Core Gentex operating expenses were $79.2 million, a slight increase from $78.3 million in Q3 2024, including acquisition-related costs and severance expenses [6][5] Future Guidance - The company anticipates a 4% decline in global light vehicle production for Q4 2025 compared to Q4 2024, with full-year 2025 production expected to decrease by 1% [18] - Updated guidance for 2025 includes consolidated revenue estimates of $2.50 – $2.60 billion, with a gross margin of 33.5% – 34% [21][18] - The company plans to continue share repurchases, having repurchased 1.0 million shares for $28.3 million in Q3 2025 [16]